Table 2.
Primary efficacy outcomes.
|
Observed Proportion of Births (%) |
Posterior mean% (95% Bayesian credible interval) |
Bayesian posterior prob. (1000 better than 200) |
|||
|---|---|---|---|---|---|
| 200 mgN = 492 | 1000 mgN = 540 | 200 mgN = 524 | 1000 mgN = 576 | ||
| Group | |||||
| Early preterm birth < 34 wka | 12/492 (2.4) | 9/540 (1.7) | 2.5 (1.2, 3.8) | 1.7 (0.7, 2.8) | 0.81 |
| Early preterm birth < 34 wkb | 12/492 (2.4) | 9/540 (1.7) | 2.9 (1.6, 4.3) | 1.7 (0.8, 2.8) | 0.91 |
| Subgroups – Birth <34 wk by baseline DHAc | |||||
| Low DHA (< 6%) b | 9/219 (4.1) | 5/249 (2.0) | 4.8 (2.3, 7.4) | 2.5 (0.8, 4.3) | 0.93 |
| High DHA (≥ 6%)b | 3/271 (1.1) | 4/289 (1.4) | 1.6 (0.4, 3.0) | 1.4 (0.3, 2.7) | 0.57 |
a
Uses the primary analysis model that drove the adaptations, which is a Bayesian binomial model.
b
Uses an alternative model that dichotomizes the continuous variable via a continuous mixture of three normal distributions.
c
Low DHA status at baseline was defined as less than 6% of total red blood cell phospholipid fatty acids.